The firm is now clinically validating a mass spec-based test for quantifying native insulin and its therapeutic analogs and another test for type 2 diabetes.
The findings demonstrate how one type of posttranscriptional modification gives RNA-binding proteins access to previously inaccessible regions of the mRNA.
